PTGER4 and osteoarthritis: In 2016, the EP4R antagonist Grapiprant (CJ-023423)18 was accepted by the FDA’s Center for Veterinary Medicine for the treatment of osteoarthritis-induced chronic inflammatory pain in dogs, highlighting the potential of EP4R antagonists for chronic pain relief19.